Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNAO1 | P09471 | 10/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 9/20 | 0.46 |
| ▸ | GNAI1 | P63096 | 9/20 | 0.46 |
| ▸ | GUSB | P08236 | 2/20 | 0.33 |
| ▸ | NCF1 | P14598 | 1/20 | 0.31 |
| ▸ | GBA1 | P04062 | 1/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18672421 | 1.00 | GNAO1 (0.46) | GNAO1GNAI3GNAI1GUSBNCF1 | |
| SCHEMBL22004465 | 0.98 | GNAO1 (0.47) | GNAO1GNAI3GNAI1GUSBNCF1 | |
| SCHEMBL24923260 | 0.95 | GNAO1 (0.45) | GNAO1GNAI3GNAI1GUSBNCF1 | |
| SCHEMBL25038693 | 0.94 | GNAO1 (0.42) | GNAO1GNAI3GNAI1NCF1 | |
| SCHEMBL18799818 | 0.91 | GNAO1 (0.45) | GNAO1GNAI3GNAI1GUSBNCF1 | |
| SCHEMBL22024307 | 0.90 | GNAO1 (0.40) | GNAO1GNAI3GNAI1GUSB | |
| SCHEMBL21191589 | 0.88 | GNAO1 (0.41) | GNAO1GNAI3GNAI1GUSB | |
| SCHEMBL22292525 | 0.87 | GNAO1 (0.40) | GNAO1GNAI3GNAI1NCF1 | |
| SCHEMBL22023882 | 0.85 | GNAO1 (0.39) | GNAO1GNAI3GNAI1GUSB | |
| SCHEMBL26653372 | 0.84 | GNAO1 (0.36) | GNAO1GNAI3GNAI1GUSBNCF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | PMV PHARMACEUTICALS, INC. | 2023-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230044826-A1 | COMPANION DIAGNOSTIC TOOL FOR MUTANT P53 REACTIVATING COMPOUNDS | TP53, TP53BP1, KRAS | GNAO1 2874/4885GNAI3 1518/4885GNAI1 1716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.